IP Library Granted Patent US 10,073,103
Granted Patent B1
US 10,073,103 · App. 15/658,920 · Granted Sep 11, 2018

Rapid measurement of total vitamin D in blood

Inventor: Tina Noyes (East Palo Alto, CA)
Assignee: Theranos IP Company, LLC
G01N33/82G01N2333/95
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,073,103
App. No.
15/658,920
Granted
Sep 11, 2018
Kind
B1
Abstract

Assays for rapid measurement of total vitamin D in blood are provided. Vitamin D is measured following the rapid and irreversible release of vitamin D due to denaturation and digestion of vitamin D binding proteins by aspartyl peptidases (e.g., pepsin) under acidic conditions. Such measurements may be made using a vitamin D binder (e.g., an antibody) to measure competition between free vitamin D and added, labeled vitamin D. Synergy between denaturation and degradation is believed to provide more rapid and more complete release of vitamin D than would occur with acid or enzyme alone. These measurements may be made using small amounts of whole blood, serum, or plasma, and are suitable for use in automated devices. These methods provide the advantages of reduced cost, increased speed, reduced discomfort to the subject, and increased availability and ease of use. Reagents, kits, devices, and systems for these assays are also disclosed.

Claims (26)

1. A method for determining the amount of vitamin D in a blood sample, wherein said blood sample comprises vitamin D and a vitamin D binding protein, the method comprising:

contacting said blood sample with a low pH composition comprising an aspartyl peptidase active at low pH, whereby a low pH diluted blood sample composition is formed, effective to at least partially denature and at least partially digest said vitamin D binding protein;

contacting said low pH diluted blood sample composition with a neutral pH composition comprising a neutral pH buffer, whereby a neutral pH diluted blood sample composition is formed, effective that said aspartyl peptidase is inactivated; and

measuring the amount of said vitamin D in said neutral pH diluted blood sample, wherein measuring the amount of said vitamin D comprises:

contacting said neutral pH diluted blood sample composition with two or more types of vitamin D binders, wherein each of said types of vitamin D binder binds specifically to vitamin D; and

adding labeled vitamin D to said neutral pH diluted blood sample composition comprising said vitamin D binders;

contacting said neutral pH diluted blood sample composition comprising said vitamin D binders with a capture surface, wherein said capture surface comprises capture elements configured to bind to each of said types of vitamin D binder; and

detecting said labeled vitamin D, wherein the amount of detected vitamin D provides a measure of the amount of vitamin D in the blood sample.

2. The method of claim 1 , wherein measuring the amount of said vitamin D comprises a competition assay measurement.

3. The method of claim 1 , wherein each of said types of vitamin D binder comprises an anti-vitamin D antibody.

4. The method of claim 1 , wherein said aspartyl peptidase active at low pH comprises pepsin.

5. The method of claim 1 , wherein said low pH comprises a pH of about pH 2.5 to about pH 4.

6. The method of claim 1 , wherein vitamin D comprises two or more of vitamin D2; vitamin D3; 25-hydroxy vitamin D2; 25-hydroxy vitamin D3; 1,25-dihydroxy vitamin D2; and 1,25-dihydroxy vitamin D3.

7. The method of claim 1 , wherein said blood sample was obtained from a fingerstick, or has a volume of less than about 150 μL, or both.

8. The method of claim 1 , wherein the blood of said blood sample is obtained from a subject by a finger-stick.

9. The method of claim 1 , wherein said determination of the amount of vitamin D in a blood sample is performed in less than about one hour after contacting said blood sample with a low pH composition comprising an aspartyl peptidase active at low pH.

10. A method for determining the amount of vitamin D in a blood sample, wherein said blood sample comprises vitamin D and a vitamin D binding protein, the method comprising:

contacting said blood sample with a low pH composition comprising an aspartyl peptidase active at low pH, whereby a low pH diluted blood sample composition is formed, effective to at least partially denature and at least partially digest said vitamin D binding protein;

contacting said low pH diluted blood sample composition with a neutral pH composition comprising a neutral pH buffer, whereby a neutral pH diluted blood sample composition is formed, effective that said aspartyl peptidase is inactivated; and

measuring the amount of said vitamin D in said neutral pH diluted blood sample.

11. The method of claim 10 , wherein measuring the amount of said vitamin D comprises: contacting said neutral pH diluted blood sample composition with two or more types of vitamin D binders, wherein each of said types of vitamin D binder comprises an anti-vitamin D antibody.

12. The method of claim 11 , further comprising contacting said neutral pH diluted blood sample composition comprising said vitamin D binders with a capture surface, wherein said capture surface comprises capture elements configured to bind to each of said types of vitamin D binder.

13. The method of claim 10 , wherein vitamin D comprises two or more of vitamin D2; vitamin D3; 25-hydroxy vitamin D2; 25-hydroxy vitamin D3; 1,25-dihydroxy vitamin D2; and 1,25-dihydroxy vitamin D3.

14. The method of claim 10 , wherein said blood sample was obtained from a fingerstick, or has a volume of less than about 150 μL, or both.

15. The method of claim 10 , wherein the blood of said blood sample is obtained from a subject by a finger-stick.

16. The method of claim 10 , wherein said determination of the amount of vitamin D in a blood sample is performed in less than about one hour after contacting said blood sample with a low pH composition comprising an aspartyl peptidase active at low pH.

Assignments (5)
CHANGE OF NAME Recorded Apr 3, 2020
From: THERANOS IP COMPANY, LLC
To: LABRADOR DIAGNOSTICS LLC
Reel/Frame 052313/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2018
From: THERANOS, INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 045205/0686 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2017
From: THERANOS INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 044838/0909 →
SECURITY INTEREST Recorded Dec 12, 2017
From: THERANOS IP COMPANY, LLC
To: FORTRESS CREDIT CORP.
Reel/Frame 044839/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2017
From: NOYES, TINA
To: THERANOS, INC.
Reel/Frame 044479/0969 →
Continuity (3)
Continuation 14819259 · Aug 5, 2015
Continuation 14203239 · Mar 10, 2014
Provisional Application 61776641 · Mar 11, 2013